Brand Name: Bydureon Generic Name: Exenatide extended-release (ER) Manufacturer: Amylin Pharmaceuticals Drug Class

ثبت نشده
چکیده

Mechanism of Action: 1,2,3,4, : Incretins, such as glucagon-like peptide-1 (GLP-1), enhance glucose-dependent insulin secretion and exhibit other antihyperglycemic actions following their release into the circulation from the gut. Exenatide extended-release is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, slows gastric emptying, reduces food intake, and promotes β-cell proliferation. Exenatide acutely improves glycemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes. Exenatide leads to a release of insulin only in the presence of elevated glucose concentrations. Insulin secretion subsides as euglycemia occurs. First-phase insulin response (release of insulin within 10 minutes following a glucose load) is lost in patients with type 2 diabetes. Loss of first-phase response is a beta cell defect. Exenatide restores first-phase insulin response to an IV bolus of glucose. Exenatide moderates glucagon secretion and lowers serum glucagon concentrations during periods of hyperglycemia. Lower glucagon concentrations lead to decreased hepatic glucose output and decreased insulin demand. Exenatide does not impair the normal glucagon response to hypoglycemia. Exenatide also slows gastric emptying thereby reducing the rate at which meal-derived glucose appears in the circulation. Exenatide extended release provides a controlled release of exenatide through Medisorb ®

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Once-Weekly Glucose-Lowering Therapy for Type 2 Diabetes

Editor’s note: Exenatide once weekly (QW), which was recently approved for patients with type 2 diabetes, has great potential as a new diabetes therapy in the primary care setting. This article, and the commentary that precedes it (p. 92), offer an overview of this new therapeutic tool and important insights about its clinical utility. In the interest of transparency, however, we want to point ...

متن کامل

Long-acting preparations of exenatide

Exenatide has been widely used for the treatment of type 2 diabetes mellitus. However, its short plasma half-life of 2.4 hours has limited its clinical application. The exenatide products on the market, twice-daily Byetta™ and once-weekly Bydureon™ (both Amylin Pharmaceuticals, San Diego, CA, USA), are still not perfect. Many researchers have attempted to prolong the acting time of exenatide by...

متن کامل

Release of levetiracetam from extended-release tablets that appear intact in patient stool

Many antiepileptic drugs (AEDs) are extended-release (ER) tablets, such that an entire day’s dose is taken only once or twice daily. A patient taking four levetiracetam ER 500 mg tablets twice daily was alarmed when, after switching from a generic manufactured by Sun to a generic manufactured by Lupin, ER tablet remnants appeared as intact tablets in his stool, suggesting no drug was absorbed. ...

متن کامل

Input Estimation for Extended-Release Formulations Exemplified with Exenatide

Estimating the in vivo absorption profile of a drug is essential when developing extended-release medications. Such estimates can be obtained by measuring plasma concentrations over time and inferring the absorption from a model of the drug's pharmacokinetics. Of particular interest is to predict the bioavailability-the fraction of the drug that is absorbed and enters the systemic circulation. ...

متن کامل

Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers.

Over the past two decades, courts have consistently ruled that the manufacturer of a brand-name prescription drug cannot be liable for injuries suffered by those taking generic imitations of its product. This meant that a patient injured by a generic drug could have no remedy at all because in many instances the generic drug manufacturer would escape liability on the ground that it did not prod...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2012